Companies
8-K ↗
JAZZ
Jazz Pharmaceuticals plc
Jazz Pharmaceuticals is a biopharmaceutical company developing life-changing medicines for rare diseases across epilepsies, cancers, and sleep disorders using small molecule and biologic modalities. The company markets several approved products including Xywav (sodium oxybate oral solution) for narcolepsy, Epidiolex (cannabidiol oral solution) for seizure disorders, the bispecific antibody Ziihera (zanidatamab-hrii) for HER2-positive biliary tract cancer, Modeyso (dordaviprone) for diffuse midline glioma, Zepzelca (lurbinectedin) for small cell lung cancer, and Rylaze (asparaginase erwinia chrysanthemi recombinant) for acute lymphoblastic leukemia, with an ongoing pipeline of early-, mid-, and late-stage rare disease programs.
$203.02+73.58%1Y
JAZZ · daily close · illustrative · 0 catalysts marked
Pipeline
Phase 3Gastric Neoplasms
Phase 3Gastroesophageal Adenocarcinoma
Phase 3Esophageal Adenocarcinoma
Phase 3Metastatic HER2-positive Breast Cancer
Phase 3Gastric Neoplasms
Phase 3Gastroesophageal Adenocarcinoma
Phase 3Esophageal Adenocarcinoma
Phase 3Biliary Tract Cancer
Phase 3Gastric Neoplasms
Phase 3Gastroesophageal Adenocarcinoma
Phase 3Esophageal Adenocarcinoma
Phase 3Biliary Tract Cancer
Phase 3Metastatic HER2-positive Breast Cancer
Phase 3Gastric Neoplasms
Phase 3Gastroesophageal Adenocarcinoma
Phase 3Esophageal Adenocarcinoma
Phase 3Biliary Tract Cancer
Phase 3Gastric Neoplasms
Phase 3Gastroesophageal Adenocarcinoma
Phase 3Esophageal Adenocarcinoma
Phase 3Metastatic HER2-positive Breast Cancer
Phase 3Gastric Neoplasms
Phase 3Gastroesophageal Adenocarcinoma
Phase 3Esophageal Adenocarcinoma
Phase 2Breast Cancer
Phase 3Metastatic HER2-positive Breast Cancer
Phase 2Breast Cancer
Phase 2Gastric Cancer
Phase 2Esophageal Cancer
Phase 2Gastroesophageal Cancer
Phase 2Colorectal Cancer
Phase 2Endometrial Cancer
Phase 2Non-Small Cell Lung Cancer
Phase 2Ovarian Cancer
Phase 2Urothelial Carcinoma
Phase 2Salivary Gland Cancer
Phase 2Pancreatic Cancer
Phase 2HER-2 Protein Overexpression
Phase 3Biliary Tract Cancer
Phase 3Metastatic HER2-positive Breast Cancer
Phase 3Gastric Neoplasms
Phase 3Gastroesophageal Adenocarcinoma
Phase 3Esophageal Adenocarcinoma
Phase 2Breast Cancer
Phase 2Breast Cancer
Phase 2Breast Cancer
Phase 2Breast Cancer
UnknownIndication pending review
Catalyst Calendar
Past (1)
NOV 17
ReadoutZiihera (zanidatamab-hrii)
“Jazz Pharmaceuticals plc issued a press release announcing positive top-line results from the Phase 3 HERIZON-GEA-01 trial evaluating Ziihera® (zanidatamab-hrii) in combination with chemotherapy, and with or without the checkpoint inhibitor tislelizumab, as a first-line treatment for HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma”